Fig 1: Stability of D2 and its efficacy in eliminating therapeutic anti-CD38 antibody interference. Results of indirect anti-human globulin (Coombs’) tests in the presence (plus sign) or absence (minus sign) of daratumumab and D2 are shown. (A) Distribution of anti-CD38 antibody titers (n = 49) and their association with clinical response status. (B) Agglutination scores comparing the efficacy of DTT and D2 in reducing therapeutic anti-CD38 antibody interference. (C) To evaluate the storage stability of D2, it was stored at 4°C, −20°C, and −80°C, and its ability to eliminate DARA interference was assessed via IAT after 1 month (D), 3 months (E), or 6 months. A solid pellet at the bottom of the tubes indicates a negative result, and suspended particles (red cell agglutinates) within the gel matrix indicate a positive test result (either a 1+ or 2+ degree of agglutination). DTT, dithiothreitol; DARA, daratumumab; IAT, indirect antiglobulin test.
Fig 2: Preparation, expression, and identification of rabbit anti-human CD38 monoclonal antibodies. (A) Flow cytometric sorting of single B cells; FITC/allophycocyanin (APC) (AF647) double-positive cells in AE gate selected. (B) Purity and molecular weight of rabbit mAbs were detected via staining with Coomassie brilliant blue. (C) ELISA analysis of rabbit mAb binding to hCD38-His. (D) ForteBio Octet determination of the affinities of rabbit mAbs toward hCD38-His. The binding affinity parameter KD was calculated, as reported using ForteBio Data Analysis Software 8.0 (Fremont, CA, USA). (E) Epitope competition assay with DARA by ForteBio. Green, A3; purple, D2. (F) Flow cytometry showing D2 and A3 binding to RBC-expressed CD38. Rabbit mAbs, rabbit anti-human CD38 monoclonal antibodies; DARA, daratumumab; RBC, red blood cell.
Supplier Page from Sino Biological, Inc. for Human CD38/ADPRC1 Gene ORF cDNA clone in cloning vector